Real-World Japanese Study of the Effectiveness and Safety of Switching From Dupilumab to Lebrikizumab in Patients with Moderate to Severe Atopic Dermatitis
- PMID: 40202458
- DOI: 10.1089/derm.2025.0046
Real-World Japanese Study of the Effectiveness and Safety of Switching From Dupilumab to Lebrikizumab in Patients with Moderate to Severe Atopic Dermatitis
Publication types
LinkOut - more resources
Full Text Sources